|Year : 2020 | Volume
| Issue : 2 | Page : 113-118
Association between maternal serum homocysteine concentrations in early pregnancy and adverse pregnancy outcomes
Chidinma Magnus Nwogu1, Kehinde Sharafadeen Okunade2, Muisi A Adenekan1, Adebayo Isaiah Sekumade1, Sarah John-olabode3, Ayodeji Ayotunde Oluwole2
1 Department of Obstetrics and Gynaecology, Lagos University Teaching Hospital, Idi-Araba, Lagos, Nigeria
2 Department of Obstetrics and Gynaecology, College of Medicine, University of Lagos, Idi-Araba, Lagos, Nigeria
3 Department of Haematology and Blood Transfusion, College of Medicine, University of Lagos, Idi-Araba, Lagos, Nigeria
|Date of Submission||04-Aug-2019|
|Date of Acceptance||27-Oct-2019|
|Date of Web Publication||3-Jun-2020|
Dr. Kehinde Sharafadeen Okunade
Department of Obstetrics and Gynaecology, College of Medicine, University of Lagos, PMB 12003, Idi-Araba, Lagos
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Background: There is still conflicting evidence on the extent to which maternal hyperhomocysteinemia is a risk factor for pregnancy complications. Aims: The study aimed to investigate the impact of elevated maternal homocysteine concentrations on adverse pregnancy outcomes among Nigerian women in Lagos. Materials and Methods: This was a prospective cohort study conducted at the Lagos University Teaching Hospital, Idi-Araba, Lagos, Nigeria. Participants were enrolled during the first trimester of pregnancy following which relevant data were obtained by the interview. Fasting blood samples were collected for the measurement of maternal homocysteine concentration using the enzyme-linked immunosorbent assay method. Pregnancy outcomes and complications were obtained by abstracting the antenatal, delivery, and newborn medical records. Preterm births, low-birth weight (LBW), and antepartum fetal death were used as confirmatory outcome variables in the final analysis. Descriptive statistics for all data were computed using SPSS version 22.0. The associations between the variables were tested and multivariate analyses were used to study the effects of the major baseline characteristics on the pregnancy outcome. P < 0.05 was considered statistically significant. Results: Hyperhomocysteinemia was recorded in 41 (24.6%) patients. Women with a high homocysteine concentration and those with a normal homocysteine level did not differ significantly in terms of age (P = 0.684), level of education (P = 0.866), and parity (P = 0.647). Women with hyperhomocysteinemia had an approximately twelve-fold higher risk of preterm birth (P = 0.001) and a ten-fold higher risk of delivering a term neonate with LBW (P = 0.004), but had no risk of antepartum fetal death (P = 0.118) compared to women with a normal homocysteine concentration. Conclusions: The prevalence of hyperhomocysteinemia among mothers in Lagos was relatively low. The associations between hyperhomocysteinemia and adverse pregnancy outcomes could have implications in future for the prevention of these adverse outcomes.
| Abstract in French|| |
Historique: Il existe encore des preuves contradictoires sur la mesure dans laquelle l'hyperhomocysteinemia maternel est un facteur de risque de complications de grossesse. Objectifs: L'étude visait à étudier l'impact des concentrations élevées d'homocystéine maternelle sur les résultats défavorables de la grossesse chez les Femmes nigérianes à Lagos. Matériel et Méthodes: Il s'agissait d'une étude de cohorte prospective menée à l'Hôpital universitaire d'enseignement de Lagos, Idi-Araba, Lagos, Nigeria. Les participants ont été inscrits au cours du premier trimestre de la grossesse, après quoi les données pertinentes ont été obtenues par l'entrevue. Des échantillons de sang à jeun ont été prélevés pour la mesure de la concentration maternelle d'homocystéine utilisant le méthode d'essais immunosorbent. Les résultats et les complications de grossesse ont été obtenus en reprochant le prénatal, l'accouchement, et le médical nouveau-né medical Dossiers. Les naissances prématurées, le faible poids à la naissance (LBW) et la mort fœtale antepartum ont été utilisés comme variables de résultats confirmatoires dans l'analyse finale. Les statistiques descriptives pour toutes les données ont été calculées à l'aide de la version 22.0 du SPSS. Les associations entre les variables ont été testées et multivariées ont été utilisées pour étudier les effets des principales caractéristiques de base sur les résultats de la grossesse. P 0,05 a été considéré statistiquement Important. Résultats: Hyperhomocysteinemia a été enregistré dans 41 (24,6%) Patients. Les femmes à forte concentration d'homocystéine et celles qui un niveau normal d'homocystéine n'a pas différé significativement en termes d'âge (P - 0.684), niveau d'éducation (P - 0.866), et parité (P - 0.647). Femmes l'hyperhomocysteinemia présentait un risque environ douze fois plus élevé de naissance prématurée (P - 0,001) et un risque dix fois plus élevé d'accouchement un terme nouveau-né avec LBW (P - 0,004), mais n'avait aucun risque de mort fœtale antepartum (P - 0,118) par rapport aux femmes ayant une homocystéine normale Concentration. Conclusions: La prévalence de l'hyperhomocysteinemia chez les mères à Lagos était relativement faible. Les associations entre L'hyperhomocysteinemia et les résultats défavorables de grossesse pourraient avoir des implications à l'avenir pour la prévention de ces résultats défavorables.
Keywords: Enzyme-linked immunosorbent assay, hyperhomocysteinemia, Lagos, low-birth weight, preterm birthMots-clés: Enzyme-linked immunosorbent assay, hyperhomocysteinemia, Lagos, low-birth weight, preterm birth
|How to cite this article:|
Nwogu CM, Okunade KS, Adenekan MA, Sekumade AI, John-olabode S, Oluwole AA. Association between maternal serum homocysteine concentrations in early pregnancy and adverse pregnancy outcomes. Ann Afr Med 2020;19:113-8
|How to cite this URL:|
Nwogu CM, Okunade KS, Adenekan MA, Sekumade AI, John-olabode S, Oluwole AA. Association between maternal serum homocysteine concentrations in early pregnancy and adverse pregnancy outcomes. Ann Afr Med [serial online] 2020 [cited 2022 Jun 27];19:113-8. Available from: https://www.annalsafrmed.org/text.asp?2020/19/2/113/285741
| Introduction|| |
In most developed countries, pregnancies are planned, complications are few, and outcomes are generally favorable for both mother and infant. Adverse outcomes are far more frequent in the developing world. The most severe adverse outcome of pregnancy is the death of the mother and/or her offspring. Even if both the mother and infant survive, pregnancy complications or problems at delivery or during the neonatal period can lead to severe maternal or infant morbidity. Vascular-related pregnancy complications are a major cause of these adverse maternal and fetal outcomes. The origin is thought to be related to early placentation, a process that involves trophoblast invasion and angiogenesis, but that is also dependent on vascular and endothelial function. Placental development in early pregnancy may be negatively influenced by the increased maternal homocysteine concentrations.
Homocysteine is the demethylated product of the essential amino acid methionine. It is metabolized by two main pathways: remethylation to methionine or transsulfuration to cystathionine and then to cysteine. A defect in either of the main pathways leads to an accumulation of homocysteine and this may be due to the congenital or acquired deficiencies of micronutrients, especially the B Vitamins (particularly folic acid). Hyperhomocysteinemia has been linked to fetal malformations and adverse pregnancy outcomes such as abruptio placentae, preeclampsia, neural tube defects, stillbirth, and recurrent miscarriage,,,,,, but the direction of causality and the clinical importance of these relationships are uncertain. The effects of homocysteine on pregnancy outcomes have also been linked with other adverse antepartum events such as oligohydramnios and meconium staining of amniotic fluid, fetal growth restriction, impairment of placental transport, and delivery of low-birth-weight (LBW) neonates, in the current pregnancy. There is still conflicting evidence on the extent to which elevated maternal homocysteine is a risk factor for pregnancy complications, so prospective, sufficiently powered studies from early pregnancy onward are required to establish this relationship. We, therefore, conducted this prospective cohort study that aimed to examine the impact of elevated maternal homocysteine concentrations in early pregnancy on certain vascular-related pregnancy complications of great clinical importance, such as spontaneous preterm birth, antepartum fetal death, and LBW in term neonates. This may subsequently allow the establishment of a clinical alarm system that will be useful as a marker to identify at-risk pregnant women to mitigate these undesirable pregnancy outcomes.
| Materials and Methods|| |
Study design and setting
This was a prospective cohort study conducted at the Antenatal Clinics and Labor Ward Complex of the Lagos University Teaching Hospital (LUTH), Idi-Araba, Lagos, Nigeria. LUTH has more than 800 beds and is located in the metropolis of Lagos in South-west Nigeria. The hospital provides services to patients from the neighboring states in South-west Nigeria. It is the largest hospital in Lagos State offering training, research, and clinical services, including prenatal, intrapartum, and postnatal care. Participants in the study were healthy pregnant women attending the antenatal clinics of the hospital between July and December 2015. The study was carried out after obtaining approval from the Health Research Ethics Committee of the LUTH, Lagos, Nigeria on May 15, 2015 (Approval number – ADM/DCST/HREC/018). Ethical principles according to the Helsinki Declaration were considered during the course of the research.
Study population and recruitment criteria
Eligible participants at enrolment were consenting women aged 18–45 years and with singleton pregnancy at gestational ages <14 weeks. Women with a history of diabetes or hypertension, HIV, current or previous history of smoking, and other described substance use were excluded from participation in the study.
Sample size determination and sampling techniques
The sample size (N) for the study was determined using the following formula:
Using data from a published study by Mascarenhas et al., the standard deviation = 6.59 μmol/L, the unit normal deviate corresponding to the desired Type I error rate of 5% at 95% confidence interval (zα/2) =1.96, the desired type II error rate of 5% (zβ) = 0.98 and between group mean difference in serum homocysteine levels = 0.87 μmol/L. Making provision for an attrition rate of 20%, the minimum sample size required was 163.6. However, for the ease of data collection, collation, and analysis, 200 women were enrolled at the point of entry for the study. Participants were enrolled by the consecutive sampling method after which informed written consent was obtained from each participant on explanation of the nature and purpose of the study.
Demographic and socioeconomic data were obtained from each participant by interview at entry to care using a pretested structured questionnaire. Venous blood samples (3–4 mL) were collected in a serum separator tube after an overnight fasting period and then transported from the antenatal clinics to the hospital main laboratory within 2 h of collection. The blood samples were processed by centrifugation at 3000 rpm to obtain the sera which were then stored at −20°C until the final analysis. Total maternal homocysteine levels in serum were analyzed by the enzyme-linked immunosorbent assay (ELISA) method using reagents from the manufacturer (Bioassay Technology Laboratory, Rockville, MD, USA).
The microtiter plate provided in the reagent kit has been precoated with a biotin-conjugated polyclonal antibody preparation which is specific for homocysteine. Standards or samples were then added to the appropriate microtiter plate wells and following this, avidin conjugated to horseradish peroxidase was added to each microplate well and incubated. Subsequently, 3,3', 5, 5'-tetramethylbenzidine (TMB) ELISA substrate solution was added to each well color change seen in those wells containing homocysteine, biotin-conjugated antibody, and enzyme-conjugated avidin. The enzyme-substrate reaction was terminated by the addition of a sulfuric acid solution and the color change was measured using an optical density (OD) spectrophotometer at a wavelength of 450 nm. The concentrations of homocysteine in the samples were then determined by comparing the OD of the samples to the standard curve.
Elevated maternal serum homocysteine was defined as serum homocysteine level >15 μmol/L (reference range: 4–15 μmol/L). The coefficient of variation within and between assays of <5% was being used. Pregnancy outcome and complications were obtained by abstracting the antenatal, delivery, and newborn medical records. The gestational duration was based on the gestation deduced from participants' last normal menstrual period confirmed or modified by ultrasound.
Outcome variables of interest and data management
Preterm births (delivery before 37 completed weeks), LBW (birth weight <2500 g), and antepartum fetal death were used as confirmatory outcome variables in the final analysis. Descriptive statistics for all data were computed using SPSS version 22.0 software (IBM, Armonk, NY, USA). Quantitative data were tested for normality with the Kolmogorov–Smirnov test. The associations between continuous variables were tested using the independent sample t- test (normal distribution) or the Mann–Whitney U-test (skewed data), whereas categorical variables were compared using the Chi-square test or the Fisher exact test, as appropriate. This was followed by multivariate analysis using binary logistic regression models to study the effects of the major baseline characteristics on the pregnancy outcome. P < 0.05 was considered statistically significant.
| Results|| |
Initially, 200 participants with singleton pregnancies at <14 weeks' gestation were enrolled. However, eight women withdrew their consent during the course of the study for personal or cultural reasons, 22 were lost to follow-up, and three women experienced mid-trimester pregnancy loss. Therefore, the final analysis included 167 women with 41 (24.6%) of these having a homocysteine concentration above the reference range (>15 μmol/L) and 126 (75.4%) having a normal homocysteine concentration. A scatter plot of serum homocysteine concentrations in the cohorts of study participants is shown in [Figure 1]. Using the 2.5 and 97.5 percentiles of the control cohort in the study population as the lower and upper reference limits, the reference range of serum homocysteine concentration in this study is 2.1–12.4 μmol/L.
|Figure 1: Scatter plot of homocysteine concentrations in the cohorts of participants|
Click here to view
Women with a high homocysteine concentration and those with a normal homocysteine level did not differ significantly in terms of age (P = 0.684), level of education (P = 0.866), and parity (P = 0.647) [Table 1]. Of the 167 participants, 21 (12.6%) had preterm births. The preterm birth rate was seven times higher among women with maternal hyperhomocysteinemia than those with a normal homocysteine concentration (P = 0.001). Among the 146 term deliveries, 17 (11.6%) patients had neonates with LBW, and the rate among women with a high homocysteine concentration is five times higher than among women with a normal homocysteine concentration (P = 0.029). There were 2 (1.2%) intrapartum stillbirths recorded, and the rate did not differ between patients with high or normal homocysteine concentrations [Table 2]. After controlling for age, parity, and level of education, mothers with hyperhomocysteinemia had an approximately twelve-fold higher risk of having preterm births [Table 3] and a ten-fold higher risk of delivering a neonate with LBW at term, compared with women with a normal homocysteine concentration [Table 4]. Maternal age >34 years was also independently associated with an increased risk of preterm birth [Table 3].
|Table 1: Distribution of participants' baseline characteristics and maternal serum homocysteine levels (n=167)a|
Click here to view
|Table 2: Bivariate analysis of maternal selenium concentrations and pregnancy outcomesa|
Click here to view
|Table 3: Bivariate and multivariate analyses of the relationships between baseline characteristics and preterm births (n=167)|
Click here to view
|Table 4: Bivariate and multivariate analyses of the relationships between baseline characteristics and low-birth weight in term neonates (n=146)|
Click here to view
| Discussion|| |
In the present study, the prevalence of maternal hyperhomocysteinemia in early pregnancy was 24.6%, and elevated maternal homocysteine concentration was significantly associated with preterm birth and LBW among term neonates. These findings could have implications for the future use of early pregnancy maternal serum homocysteine concentration as a marker of adverse delivery outcomes.
The prevalence of serum hyperhomocysteinemia recorded is similar to the rate of 22.2% found by Bergen et al. but much lower than the rate of 50.0% reported by Visternicean in Moldova. This variation may be due to the geographical/racial differences and lower cutoff value (12 μmol/L) for elevated serum homocysteine level chosen by Visternicean, whereas the higher cutoff value for the current study (15 μmol/L) was based on the reference range for normal homocysteine levels proposed by Abbassi-Ghanavati et al. However, the reference values for serum homocysteine recorded in this current study (2.1–12.4 μmol/L) are almost similar to that by Visternicean among Moldovan pregnant women but lower than that reported by Abbassi-Ghanavati et al. among Caucasian women in the United States. This suggests that our study could have reported a higher proportion of women with maternal hyperhomocysteinemia just as reported by Visternicean.
Preterm birth rate recorded in this study was 12.6%, and this was more than double the incidence of 5.0% reported by our team among similar cohorts of participants in the same setting in Lagos. This may be explained by the change in the profile of pregnant women seen in our tertiary hospital setting as more women now embrace institutional deliveries compared to what was obtainable at the time of our previous study in 2013. However, the incidence of preterm birth in this highly selected cohorts was only slightly higher than the rate quoted in the study by Edison et al. in South Carolina, USA (6.6%), but within the range of 5%–25% reported in a study conducted in a regional tertiary hospital in Nigeria by Ezechukwu et al. This was probably due to the similarities in the populations of participants used in all these studies. However, just like our study, Vollset et al. and Kramer et al. reported statistically significant relationships between maternal hyperhomocysteinemia and preterm births. About a tenth (11.6%) of the mothers in our study delivered LBW babies at term, and there was a statistically significant association between elevated maternal serum homocysteine in early pregnancy and delivery of LBW babies. This is similar to the findings from most previous studies,, but at variance to the studies by Infante-Rivard et al. in 2003 and Dodds et al. in 2008. The variations in the findings of these latter studies compared to the current study and others were largely attributed to the differences in their study designs. Two of the 167 women had an antepartum fetal death, and we reported no significant association between early pregnancy maternal hyperhomocysteinemia and the incidence of antepartum fetal death. This is similar to the findings from other previous studies., The low incidence of fetal death reported may reflect the study population which comprised only of healthy, low risk, and predominantly low parous pregnant women. The current study was hospital-based, limiting the generalizability of the findings to the entire population of pregnant women in Lagos. It was also difficult to determine, through recall, the number of folic acid tablets consumed by the mothers before their sample collection and homocysteine assay, this may be a confounding factor, especially due to the fact that folic acid is routinely used by most in their first trimester of pregnancies even before their antenatal care booking. It is also important to highlight that the association observed in the present study does not necessarily indicate causality. However, this is the only known study among Sub-Saharan African women that examined the possible effects of a high homocysteine concentration on pregnancy outcomes while carefully adjusting for confounding factors. This study thus provides valuable information for future robust longitudinal studies among pregnant women in Nigeria, which could inform future policies on the use of early pregnancy maternal homocysteine concentration as a predictive marker of adverse outcomes in pregnancy.
| Conclusions|| |
This study showed a relatively low prevalence of early pregnancy maternal hyperhomocysteinemia among women in Lagos. The significant associations observed between maternal hyperhomocysteinemia and adverse pregnancy outcomes could have implications on the future prevention of these adverse effects through the routine measurements of maternal serum homocysteine concentrations in at-risk pregnant women in early pregnancy. However, further robust and longitudinal research is needed to answer some of the major reservations that remain from the present study such as the overall impacts of the variously identified confounders on these relationships. This may also in the long term suggest the crucial role of nutritional folate fortification before and during pregnancy as the two pathways of homocysteine metabolism require folate (mostly) and Vitamin B6/B12. Therefore, mandatory prophylactic folate supplementations in at-risk women of reproductive age such as those in regions with a high burden of nutritional deficiencies, malaria, and sickle-cell anemia may have merit in the nearest future.
Financial support and sponsorship
This study was financially supported, in part, by the Fogarty International Center and National Institute of Mental Health of the National Institutes of Health (NIH) with award No. D43TW010543.
Conflicts of interest
There are no conflicts of interest.
| References|| |
World Health Organization. Trends in Maternal Mortality: 1990-2013. Estimates by WHO, UNICEF, UNFPA, the World Bank and the United Nations Population Division. Geneva: World Health Organization; 2014.
Tinker A. Women's health: The unfinished Agenda. Int J Gynaecol Obstet 2000;70:149-58.
Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010;376:631-44.
Steegers-Theunissen RP, Steegers EA. Nutrient-gene interactions in early pregnancy: A vascular hypothesis. Eur J Obstet Gynecol Reprod Biol 2003;106:115-7.
Mascarenhas M, Habeebullah S, Sridhar MG. Revisiting the role of first trimester homocysteine as an index of maternal and fetal outcome. J Pregnancy 2014;2014:123024.
Miner SE, Evrovski J, Cole DE. Clinical chemistry and molecular biology of homocysteine metabolism: An update. Clin Biochem 1997;30:189-201.
den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, et al.
Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N
Engl J Med 1996;334:759-62.
Wouters MG, Boers GH, Blom HJ, Trijbels FJ, Thomas CM, Borm GF, et al.
Hyperhomocysteinemia: A risk factor in women with unexplained recurrent early pregnancy loss. Fertil Steril 1993;60:820-5.
Dekker GA, de Vries JI, Doelitzsch PM, Huijgens PC, von Blomberg BM, Jakobs C, et al.
Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 1995;173:1042-8.
Burke G, Robinson K, Refsum H, Stuart B, Drumm J, Graham I. Intrauterine growth retardation, perinatal death, and maternal homocysteine levels. N
Engl J Med 1992;326:69-70.
Mills JL, McPartlin JM, Kirke PN, Lee YJ, Conley MR, Weir DG, et al.
Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet 1995;345:149-51.
Ananth CV, Elsasser DA, Kinzler WL, Peltier MR, Getahun D, Leclerc D, et al.
Polymorphisms in methionine synthase reductase and betaine-homocysteine S-methyltransferase genes: Risk of placental abruption. Mol Genet Metab 2007;91:104-10.
Murphy MM, Scott JM, Arija V, Molloy AM, Fernandez-Ballart JD. Maternal homocysteine before conception and throughout pregnancy predicts fetal homocysteine and birth weight. Clin Chem 2004;50:1406-12.
Jansson T. Novel mechanism causing restricted fetal growth: Does maternal homocysteine impair placental amino acid transport? J Physiol 2009;587:4123.
Fryer AA, Emes RD, Ismail KM, Haworth KE, Mein C, Carroll WD, et al.
Quantitative, high-resolution epigenetic profiling of CpG loci identifies associations with cord blood plasma homocysteine and birth weight in humans. Epigenetics 2011;6:86-94.
Charan J, Biswas T. How to calculate sample size for different study designs in medical research? Indian J Psychol Med 2013;35:121-6.
] [Full text]
Abbassi-Ghanavati M, Greer LG, Cunningham FG. Pregnancy and laboratory studies: A reference table for clinicians. Obstet Gynecol 2009;114:1326-31.
Bergen NE, Jaddoe VW, Timmermans S, Hofman A, Lindemans J, Russcher H, et al.
Homocysteine and folate concentrations in early pregnancy and the risk of adverse pregnancy outcomes: The generation R study. BJOG 2012;119:739-51.
Visternicean E. Homocysteine and recurrent miscarriage. Moldovan Med J 2017;60:15-9.
Oluwole AA, Adegbesan-Omilabu MA, Okunade KS. Preterm delivery and low maternal serum cholesterol level: Any correlation? Niger Med J 2014;55:406-10.
] [Full text]
Edison RJ, Berg K, Remaley A, Kelley R, Rotimi C, Stevenson RE, et al.
Adverse birth outcome among mothers with low serum cholesterol. Pediatrics 2007;120:723-33.
Ezechukwu CC, Ugochukwu EF, Egbuonu I, Chukwuka JO. Risk factors for neonatal mortality in a regional tertiary hospital in Nigeria. Nig J Clin Pract 2004;7:50-2.
Vollset SE, Refsum H, Irgens LM, Emblem BM, Tverdal A, Gjessing HK, et al.
Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: The hordaland homocysteine study. Am J Clin Nutr 2000;71:962-8.
Kramer MS, Kahn SR, Rozen R, Evans R, Platt RW, Chen MF, et al.
Vasculopathic and thrombophilic risk factors for spontaneous preterm birth. Int J Epidemiol 2009;38:715-23.
Infante-Rivard C, Rivard GE, Gauthier R, Théorêt Y. Unexpected relationship between plasma homocysteine and intrauterine growth restriction. Clin Chem 2003;49:1476-82.
Dodds L, Fell DB, Dooley KC, Armson BA, Allen AC, Nassar BA, et al.
Effect of homocysteine concentration in early pregnancy on gestational hypertensive disorders and other pregnancy outcomes. Clin Chem 2008;54:326-34.
Refsum H, Nurk E, Smith AD, Ueland PM, Gjesdal CG, Bjelland I, et al.
The hordaland homocysteine study: A community-based study of homocysteine, its determinants, and associations with disease. J Nutr 2006;136:1731S-40S.
[Table 1], [Table 2], [Table 3], [Table 4]